What real-time clinical trials actually demand
The FDA has been running proof-of-concept work with AstraZeneca and Amgen on something it's calling Real-Time Clinical Trials, where sponsors transmitting predefined safety signals and efficacy endpoints to the agency as a trial runs, instead of batching everything up for a submission months or years later. Clinical Leader and Clinical Tech Leader did a three-part series on it (what it is and why it matters, what it demands from your tech stack, the unresolved risks and rules). Worth a read if you're in this industry. What stuck with me, though, is that this gets talked about as a regulatory shift when it's really an infrastructure one.
The upside is easy to see. Earlier signal detection, more adaptive trial design, shorter timelines. Nobody's going to argue against catching a safety problem sooner. But "real time" is doing more work in that phrase than it first appears.
Most of the value clinical data pipelines provide today happens downstream. Sites enter data on their own schedule, sponsors clean it, reconcile it, run it through validation, and eventually something regulator-ready comes out the other end. That cleanup cycle isn't overhead — it's where a lot of the actual data quality work happens. RTCT asks teams to surface signals before that cycle finishes, which means a slow site or an inconsistent process stops being something the pipeline quietly absorbs and starts being a visible gap.
You can't bolt real-time reporting onto a batch-shaped system and call it done. Teams that already have boring, validated, end-to-end pipelines with traceability built in are probably better positioned here than teams adding a dashboard on top and hoping.
There's also a governance question that doesn't seem fully answered yet. Who's accountable when a real-time signal fires mid-trial — the sponsor, the DSMB, the agency? How do you preserve blinding when data is visible continuously instead of at checkpoints? RTCT isn't replacing GCP or ICH E6, it's adding a signal layer on top of them, and stacking new obligations on existing frameworks without settling who owns what feels like the kind of thing that tends to surface later as a problem.
If AI ends up doing the signal detection itself, explainability matters more than it used to, since a regulator may be looking at the signal almost as soon as it appears.
This is still pilot-stage, and a lot could change before it scales. But it seems worth getting the data pipeline boring and reliable now rather than later.